Immuron Limited Stock News

Immuron achieved 60% YoY growth in worldwide product sales in Q3 FY20. YTD March 31, FY20 worldwide sales reached AU $2.67M, increasing 57% YoY. In Australia, Q3 FY20 gross sales grew by 35% YoY to

IMMURON LTD/S (NASDAQ:IMRN) and Intec Pharma (NASDAQ:NTEC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends,

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) * Forty Seven Inc (NASDAQ: FTSV) * Masimo Corporat

Intra-Cellular Therapies (NASDAQ:ITCI) and IMMURON LTD/S (NASDAQ:IMRN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 24) * BELLUS Health Inc (NASDAQ: BLU) * Global Cord

The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the Company. The keystone of this strategy will be the preservat

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Key Highlights: Strong continued growth of Travelan® sales reported in all marketsGlobal sales reached USD $1.1 million (AUD $1.68 million) for first half FY 2020 up 55% from.

Key Highlights: Wuhan coronavirus outbreak expanding to global health emergencyOutbreak while viral in nature highlights the role of global travel leading to respiratory and.

Key Highlights: Strong continued growth of Travelan® sales reported in all marketsNorth American Travelan® sales up by 98% YoY in the first half of FY20Immuron achieved 55% YoY.

MELBOURNE, Australia, Jan. 08, 2020 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.

Key Points Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD)Phase 3 clinical trial of IMM-124E to.

The big shareholder groups in Immuron Limited (ASX:IMC) have power over the company. Generally speaking, as a company...

MELBOURNE, Australia, Nov. 04, 2019 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.

This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Synthesis Energy Systems (NASDAQ: SES ) s